Amylyx director granted 24,372 stock options

Amylyx Pharmaceuticals director George M. Milne Jr. received a grant of stock options covering 24,372 shares of common stock.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals director George M. Milne Jr. received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or the next annual meeting, as long as he continues serving the company.

Insider Trade Summary

Grant/Award: 24,372 shares

Grant/Award 1 txn

Insider MILNE GEORGE M JR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	24,372	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 24,372 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Key Figures

Option grant size: 24,372 options Exercise price: $14.31 per share Post-grant holdings: 24,372 options +2 more

5 metrics

Option grant size 24,372 options Stock Option (right to buy) granted to director

Exercise price $14.31 per share Conversion or exercise price of options

Post-grant holdings 24,372 options Total options held following transaction

Expiration date June 3, 2036 Option expiration date

Latest vest date June 4, 2027 Latest possible full vesting date per footnote

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, continuous service, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer"

exercise price financial

"conversion_or_exercise_price: "14.3100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amylyx (AMLX) director George M. Milne Jr. receive in this Form 4?

George M. Milne Jr. received a grant of stock options for 24,372 shares of Amylyx common stock. These options are part of his director compensation and allow him to buy shares at a fixed exercise price if he remains in service until vesting.

What is the exercise price of the Amylyx (AMLX) stock options granted?

The granted stock options have an exercise price of $14.31 per share. This means Milne can purchase Amylyx common stock at $14.31 in the future, regardless of the market price, once the options have vested and before they expire.

When do the new Amylyx (AMLX) stock options vest for George M. Milne Jr.?

The options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting. Vesting requires Milne’s continuous service to Amylyx through that date, aligning his compensation with ongoing board participation and company oversight.

When do the Amylyx (AMLX) director stock options granted in this filing expire?

These stock options expire on June 3, 2036. After that expiration date, Milne can no longer exercise them to purchase Amylyx common shares, even if they have vested, so any exercise must occur before that deadline.

How many Amylyx (AMLX) options does George M. Milne Jr. hold after this grant?

Following this transaction, Milne holds 24,372 stock options directly according to the filing. All of these options relate to Amylyx common stock and reflect his position from this grant, subject to future vesting and any later transactions.

Is this Amylyx (AMLX) Form 4 transaction a market purchase or sale of shares?

This transaction is a grant of stock options, not a market purchase or sale of existing shares. The Form 4 classifies it as a grant, award, or other acquisition, providing potential future ownership rather than immediate open-market trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILNE GEORGE M JR

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.31	06/04/2026		A		24,372		(1)	06/03/2036	Common Stock	24,372	$0	24,372	D

Explanation of Responses:

1. The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

	/s/ Joshua B. Cohen, as Attorney in Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)